GERN
Geron Corporation Healthcare - Biotechnology Investor Relations →
Geron Corporation (GERN) closed at $1.46 as of 2026-03-20, trading 41.3% below its 200-week moving average of $2.49. This places GERN in the extreme value zone. The stock is currently moving closer to the line, down from -36.5% last week. The 14-week RSI sits at 54, indicating neutral momentum.
Trading volume is running at 1.9x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.87 ratio) is neutral — neither side is clearly dominating.
Over the past 1498 weeks of data, GERN has crossed below its 200-week moving average 31 times. On average, these episodes lasted 32 weeks. Historically, investors who bought GERN at the start of these episodes saw an average one-year return of +15.4%.
With a market cap of $935 million, GERN is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -33.0%. The stock trades at 4.1x book value.
Share count has increased 64.0% over three years, indicating dilution.
Over the past 28.8 years, a hypothetical investment of $100 in GERN would have grown to $24, compared to $1118 for the S&P 500. GERN has returned -4.9% annualized vs 8.8% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: GERN vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After GERN Crosses Below the Line?
Across 31 historical episodes, buying GERN when it crossed below its 200-week moving average produced an average return of +11.1% after 12 months (median -5.0%), compared to +12.2% for the S&P 500 over the same periods. 42% of those episodes were profitable after one year. After 24 months, the average return was +2.6% vs +16.2% for the index.
Each line shows $100 invested at the moment GERN crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
GERN has crossed below its 200-week MA 31 times with an average 1-year return of +15.4% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 1997 | Aug 1997 | 5 | 29.1% | +26.9% | -79.2% |
| Nov 1997 | Jan 1998 | 8 | 9.7% | +30.8% | -83.1% |
| Jun 1998 | Nov 1998 | 21 | 52.7% | +27.8% | -82.8% |
| Apr 1999 | Apr 1999 | 3 | 4.8% | +196.6% | -83.3% |
| Oct 1999 | Nov 1999 | 1 | 4.2% | +134.9% | -83.7% |
| Nov 1999 | Nov 1999 | 1 | 1.1% | +126.8% | -84.3% |
| Mar 2001 | Aug 2001 | 24 | 36.5% | -42.6% | -89.3% |
| Sep 2001 | Oct 2003 | 109 | 88.3% | -73.6% | -89.4% |
| Oct 2003 | Jan 2005 | 62 | 43.1% | -37.9% | -87.8% |
| Jan 2005 | May 2005 | 16 | 23.8% | -3.3% | -80.7% |
| Jun 2005 | Jun 2005 | 1 | 3.1% | -6.0% | -78.5% |
| May 2006 | Oct 2006 | 25 | 21.7% | +2.9% | -78.6% |
| Nov 2006 | Dec 2006 | 1 | 0.1% | -17.3% | -80.2% |
| Feb 2007 | May 2007 | 13 | 16.9% | -38.0% | -80.7% |
| Jun 2007 | Oct 2007 | 16 | 27.1% | -49.4% | -80.5% |
| Oct 2007 | Jan 2009 | 66 | 63.4% | -55.9% | -78.9% |
| Feb 2009 | Jun 2009 | 16 | 43.3% | -11.6% | -75.8% |
| Sep 2009 | Oct 2009 | 1 | 1.9% | -13.6% | -75.5% |
| Oct 2009 | Mar 2010 | 18 | 15.7% | -8.7% | -74.7% |
| Mar 2010 | Sep 2013 | 184 | 74.9% | -19.0% | -73.8% |
| Oct 2013 | Oct 2013 | 1 | 3.5% | -36.1% | -49.8% |
| Mar 2014 | Jun 2014 | 13 | 40.6% | +150.9% | -15.6% |
| Jul 2014 | Nov 2014 | 17 | 25.4% | +71.5% | -41.5% |
| Feb 2016 | Feb 2016 | 3 | 5.7% | -17.1% | -44.5% |
| May 2016 | May 2016 | 2 | 4.2% | -3.0% | -45.3% |
| Jun 2016 | Mar 2018 | 92 | 35.9% | -4.7% | -47.3% |
| Sep 2018 | Jun 2020 | 92 | 66.8% | -23.3% | -17.0% |
| Jul 2020 | Jun 2022 | 102 | 44.5% | -37.7% | -28.4% |
| Oct 2023 | Nov 2023 | 6 | 6.5% | +138.7% | -19.3% |
| Jan 2024 | Feb 2024 | 3 | 4.3% | +52.9% | -22.8% |
| Feb 2025 | Ongoing | 56+ | 56.7% | Ongoing | -17.0% |
| Average | 32 | — | +15.4% | — |
Frequently Asked Questions
Is GERN below its 200-week moving average?
Yes. As of 2026-03-20, Geron Corporation (GERN) is trading 41.3% below its 200-week moving average of $2.49. The current price is $1.46.
What is GERN's 200-week moving average price?
Geron Corporation's 200-week moving average is $2.49 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when GERN drops below its 200-week moving average?
GERN has crossed below its 200-week moving average 31 times in our data. On average, buying at that moment produced a one-year return of +15.4%. These dips have historically been decent entry points. These episodes lasted 32 weeks on average.
Is GERN a good value right now?
Here's what our data says about GERN as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 54. Free cash flow is currently negative. Return on equity is -33.0%. Price-to-book is 4.1x. This is not a buy or sell recommendation — always do your own research.
How does GERN compare to the S&P 500?
Over the past 28.8 years, $100 invested in GERN would have grown to $24, compared to $1118 for the S&P 500. That's -4.9% annualized vs 8.8% for the index. GERN has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20